Eisai and Biogen Idec Collaboration Set to Develop and Commercialize Treatments for Alzheimer’s

Eisai Co., Ltd. (OTCMKTS:ESALY) and Biogen Idec (NASDAQ: BIIB) are collaborating to develop and commercialize two of Eisai’s clinical candidates for Alzheimer’s disease: E2609, a β-site amyloid precursor protein cleaving enzyme (BACE) inhibitor, and BAN2401, an anti-Aβ antibody. The agreement also provides Eisai the option to jointly develop and commercialize two of Biogen Idec’s candidates for Alzheimer’s, the anti-amyloid beta (Aβ) antibody BIIB037 and an anti-tau monoclonal antibody.

As quoted in the press release:

The collaboration initially will be centered on the co-development and co-commercialization of Eisai’s two candidates: E2609, a β-site amyloid precursor protein cleaving enzyme (BACE) inhibitor, and BAN2401, an anti-Aβ antibody. These candidates have the potential to reduce Aβ plaques that form in the brains of patients with AD and to stop the formation of new plaques, potentially improving symptoms and suppressing disease progression.

Click here to read the Eisai Co. Ltd. (OTCMKTS:ESALY) press release